Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$21.89 USD
+0.09 (0.41%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $21.89 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth D Momentum A VGM
Price, Consensus and EPS Surprise
CPRX 21.89 +0.09(0.41%)
Will CPRX be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for CPRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CPRX
Zacks.com featured highlights include Vertiv, Limbach, Atour Lifestyle and Catalyst Pharmaceuticals
Pick These 4 Solid Net Profit Margin Stocks to Boost Portfolio Return
CPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
CPRX or STVN: Which Is the Better Value Stock Right Now?
What Makes Catalyst (CPRX) a Good Fit for 'Trend Investing'
Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug Lumryz
Other News for CPRX
Biotech Momentum Trades For The Q4 Rally
Catalyst Pharmaceuticals price target raised by $1 at BofA, here's why
Promising Outlook and Strategic Growth Support Buy Rating for Catalyst Pharma
STATE STREET CORP's Strategic Reduction in Catalyst Pharmaceuticals Holdings
Capricor reports positive long-term data for DMD drug deramiocel